JPMorgan analyst Anupam Rama lowered the firm’s price target on Vera Therapeutics (VERA) to $52 from $53 and keeps an Overweight rating on the shares. The firm updated the company’s model.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics’ Atacicept Shows Promising Phase 3 Results and Regulatory Progress, Earning Buy Rating
- Vera Therapeutics Announces Promising Phase 3 Trial Results
- Vera Therapeutics reports ‘positive’ data from ORIGIN Phase 3 trial of atacicept
- Vera Therapeutics Reports Increased Losses Amid R&D Expansion
- Vera Therapeutics: Strong Financial Position and Promising Pipeline Justify Buy Rating